Key points are not available for this paper at this time.
Design
Review
Bradykinin augmentation merits exploration as a cardiovascular therapeutic target; leaves open confirmation of clinical benefit in prospective trials.
Bradykinin is a vasoactive kinin known to be involved in many biologic processes. Levels of bradykinin have been shown to be elevated in a number of cardiac diseases. It is thought that these elevated levels play a protective role in cardiovascular diseases. Preliminary studies have demonstrated that bradykinin may have beneficial effects on a wide spectrum of cardiovascular disorders. Though much study is still required, bradykinin augmentation represents an exciting new target for the treatment of cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Palkhiwala et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: